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SUMMARY: The transcriptional regulation of neuropeptide genes by cAMP is often direeted by a cAMP responsive 
enhancer (CRE) upstream to the promoter of the genes. The identity of the CRE was determined by transient 
transfection experiments and has the consensus sequence of 5'-TGACGTCA-3'. A large family of transcription 
factors have been identified whieh recognize the CRE. Transient transfection assays that employed expression of 
these faetors driven by vital promoters have determined they can transactivate the neuropeptide gene promoters. 
Because of the large number of factors that have been identified as being able to recognize the CRE, it has been 
difficuh to determine which factors mediate in vivo the transactivation of a particular CRE. Using a dominant 
negative mutant of one of these factors, CREB, it has been determined that both CREB as weil as other factors which 
do not interact with CREB may mediate the cAMP response of the somatostatin gene. 
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I. I N T R O D U C T I O N  
Several neuropeptides increase in expression in re- 
sponse to increased levels of cellular cAMP (10,14,23). 
The mechanism behind this induction remained unclear 
until the cloning of the genes for these neuropeptides. It 
has since beeome apparent that comparable elements up- 
stream to the promoters in these genes control their re- 
sponse to cAMP (4,24,28). Extensive study of these 
cAMP-responsive enhancers (CREs) revealed that eren 
though the sequences are similar there are significant 
functional differences among them (7). These variations in 
the basic motif are likely to confer to the enhancer distinct 
affinities to the numerous transcription factors that can 
recognize the CRE, yielding different transeriptional re- 
sponses to cellular stimuli. The first cloned CRE-binding 
protein, CREB, was isolated using the CRE from the so- 
matostatin promoter as a probe (12,15). CREB falls into 
the class of basic region leucine zipper (bZIP) transcrip- 
tion factors. These factors have a transactivation domain 
at the amino-terminus and domains that function in the 
dimerization of the protein and the reeognition of the DNA 
enhancer sequence at the carboxy-terminus. Since the 
original isolation of CREB, a large family of related pro- 
teins have been identified that recognize the CRE and are 
also bZIP proteins (13,16,21). Although all of these fac- 
tors can dimerize with themselves (homodimers), some 
are also able to form dimers with each other (hetero- 
dimers). Thus, the complex activities of the CRE se- 
quences are matched by the large number of factors, both 
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as homodimers and heterodimers, whieh can reeognize 
them. 
Experiments to determine the transcriptional charac- 
teristies of the different CREs, the ability of each factor to 
transactivate the different CREs, and the mechanism be- 
hind the transactivation have been performed both in vitro 
with cell-free systems and in vivo by transfection into ap- 
propriate cell lines. Although cell-free systems have pro- 
duced significant results, they are not able to mimie the 
complex signal transduction pathways present in whole 
cells. Transfection of DNA eonstruets into cell lines has 
been used to a mueh greater extent in determining the 
functional charaeteristies of the CREs and CRE-binding 
protein8. 
Analysis of the CRE. The CRE was first identified in the 
genes for phosphoenolpyruvate carboxykinase (26,31) 
and the neuropeptides proenkephalin (4) and somato- 
statin (24). The minimal sequence required to maintain 
the cAMP response was determined by transfection of 
constructs consisting of the upstream regions placed 5' to 
a minimal viral promoter controlling the expression of a 
reporter gene, chloramphenicol acetyhransferase (CAT). 
Deletional analysis of the upstream regions of these and 
other genes identified an eight base pair (bp) consensus 
sequence, 5'-TGACGTCA-3'. Experiments using the en- 
dogenous promoter of somatostaün revealed that the CRE 
also acts as a basal level activator. Unstimulated expres- 
sion of the somatostaün promoter decreases 10-fold upon 
deletion of the CRE (2). 
The sequence of the minimal CRE varies among cyclic 
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AMP (cAMP)-responsive genes. A number of genes have 
the perfect palindromic sequence, 5'-TGACGTCA-3' 
(24,27,30). However, other genes only have a single copy 
of the inverted repeat, 5'-CGTCA-3' (4,26). Still another 
has the inverted repeats, but they are separated by a num- 
ber of nucleotides (28). The importance of the inverted 
repeat vs. the single copy CRE is currently unclear. How- 
ever, point mutations within the palindromic CRE indicate 
that the two copies of the repeat are not equivalent. In the 
glycoprotein o~-subunit gene, both mutant sequences 5'- 
AGACGTCA-3' and 5'-TGACGTCT-3' resuh in reduced 
basal activities (8). However, the 5' mutation still elicits a 
cAMP response whereas the 3' mutation is insensitive to 
cAMP. 
The activity of a CRE sequence depends on a number 
of parameters, including the sequenees adjacent to the 
CRE, the promoter to which the CRE is attached, and the 
cell type in which the activity is being assayed. Each of 
these has been analyzed by transfection experiments. 
Placement of CREs from a number of different genes on 
an identical promoter has revealed significant functional 
differences. The consensus CRE sites and adjacent se- 
quences from the glucagon ( - 2 9 0  to -268) ,  parathyroid 
hormone ( - 7 9  to -62) ,  glycoprotein a-subunit ( - 1 2 8  to 
-111) ,  and somatostatin ( - 5 6  to - 3 3 )  genes were 
placed upstream to the glyeoprotein ct-subunit promoter 
deleted of all endogenous upstream regulatory sequences 
(7). Eren though each of these CREs includes the identical 
eight bp palindrome, they conferred different basal and 
stimulated activities on the promoter. The glucagon and 
parathyroid constructs increased basal activity by only 
1.5-fold and produced an 8-fold increase in response to 
cAMP. In contrast, the «-subunit and somatostatin CREs 
produced basal activities of 7- to 10-fold and stimulated 
responses of 20-fold. Thus, the activity of a CRE se- 
quence is modulated by sequences immediately adjacent 
to it. 
Both promoter effects and eell-type effects were identi- 
fied using the CRE from the glycoprotein ct-subunit gene 
(17). The o~-subunit CRE has no effect on the basal activ- 
ity of the minimal Œ-subunit promoter when expressed in 
INRI-G9 cells, a rat islet cell line. However, when placed 
in front of the minimal somatostatin promoter, basal activ- 
ity increased by 36-fold. This large difference in basal 
activity, although directed by the promoter, is dependent 
on the ceU line used. When these eonstructs are trans- 
fected into JEG-3 cells, a human placental cell line, both 
produce a 2.5- to lO-fold increase in basal activity. 
In addition to the interactions between cAMP-respon- 
sive elements and their promoters as described above, 
another level of complexity is added by the interaction 
between CREs and adjacent enhancer sequences. The 
CRE located in the glycoprotein a-subunit gene interacts 
with cis-acting sequences upstream to the enhaneer. This 
CRE consists of two identical 18 bp repeats in which 
reside a perfect 8 bp CRE. Immediately upstream to these 
CREs lies a tissue-specific enhancer which acts to increase 
both basal and samulated activity by 3- to 5-fold and is 
completely dependent on the CRE for acüvity (6,17). 
CRE-binding proteins. An explanation for the complex 
pattern of responses among individual CREs is that a vari- 
ety of different CRE-binding proteins exist, each with its 
own unique affinity and activity. The initial isolation of 
some of these proteins has confirmed this hypothesis and 
has identified a complex super-family of genes that en- 
code CRE-binding proteins. All of these factors isolated to 
date share the common structural elements of a carboxy- 
terminal basic DNA binding region and a leucine zipper 
motif (18). Dimerization of these factors is mediated by 
the leucine zipper which consists of four to five ieucines 
separated from each other by seven amino acids. The 
zippers interact with each other to form a coiled-coil struc- 
ture (25). The primary sequence of amino acids in the 
basic DNA binding domain varies slightly among the dif- 
ferent CRE binding proteins, with greater than 50% of the 
residues present being either lysine or arginine. These 
factors bind to DNA only as dimers, and each can form a 
homodimer. Several factors have been shown to form he- 
terodimers. The factors CRE-BP1 and CRE-BP2, for in- 
stance, readily form heterodimers with c-jun, a transcrip- 
tion factor in the protein kinase C signal transduction 
pathway (16,20). This may represent a mechanism for 
crosstalk between the kinase C and kinase A pathways. 
In addition to the DNA-binding and leucine zipper do- 
mains, all of the CRE binding proteins have amino-ter- 
minal regions which are involved in transcriptional activa- 
tion. Although they are poorly conserved among the class 
as a whole, they generally have consensus phosphoryla- 
tion sites for a number of different protein kinases. Trans- 
fection experiments have been used extensively to analyze 
the role of phosphorylation in the mechanism of transacti- 
ration by CREB. In some of these experiments, the F9 cell 
line has been used because it has little endogenous activity 
on the CRE. Here, the reporter gene containing a CRE 
sequenee upstream to the promoter is cotransfeeted with a 
cDNA for CREB driven by a viral promoter and with the 
cDNA for protein kinase A (PKA) also driven by a vital 
promoter. The CREB cDNA can be altered by standard 
molecular biological techniques to produce proteins with 
point mutations or with entire regions deleted. An alterna- 
tive technique has been used which involves creating a 
fusion protein between CREB and the DNA binding do- 
main from the yeast transcription factor, GAL4. In this 
case, the GAL4 enhancer is placed upstream to the re- 
porter gene. The strength of this technique is that cells 
with an endogenous cAMP response can be used to ana- 
lyze CREB mutants because only the CREB fusion pro- 
teins can bind to the reporter construct and stimulate 
transactivation. Experiments using these techniques 
showed that substitution of the serine in the PKA site with 
either alanine, glutamic acid, or aspartic acid severely 
inhibited the ability of CREB to activate transcription 
(11,19). The phosphorylation of CREB by PKA is, how- 
ever, not sufficient to produce a fully active transcription 
factor. Additional serine-rieh sequenees near the kinase A 
site are also necessary for activity (19). Phosphopeptide 
mapping of mutant CREB proteins expressed in JEG-3 
cells indicated that these "phosphorylation boxes" are 
modified subsequent to the primary phosphorylation by 
PKA. Two of these elements, PDE 1 and PDE 2, are 




absolutely required for eomplete aetivity. The observation 
that CREB requires muhiple phosphorylations to be fully 
active implies that several signaling pathways acting 
through different kinases could control the activity of 
CREB. 
Because cells express multiple CRE binding proteins, it 
has been difficult to determine exactly whieh factors are 
involved in the transactivation of any particular CRE. One 
method to approach this question would be to eliminate 
particular factors and assess the remaining cAMP re- 
sponse. We have been able to do this by using a dominant 
repressor of CREB. This factor, KCREB, is a mutated 
form of CREB that has a single point mutation in the 
DNA-binding domain. This mutation not only blocks the 
ability of the KCREB homodimer to bind DNA, but also 
inhibits the ability of CREB to bind DNA when in a hetero- 
dimer with KCREB (29). Transfection experiments 
showed that KCREB will block CREB when both are ex- 
pressed in the F9 cell line. KCREB was then expressed in 
the CA-77 cell line which endogenously expresses CREB 
and produces a strong cAMP-induced expression of the 
somatostatin promoter. These experiments revealed that 
the somatostatin CRE may be transactivated both by 




Scintillation counter, model LS 1710, Beckman 1 
Luminometer, Model 6500, Packard 2 
Laminar flow hood, model B40-112, Baker 3 
Incubator, 5% CO z and 3% CO2, Model 2710, Queue 
Systems 4 
pH meter, model 240, Corning s 
Speedvac, system SSI, Savant 6 
Microcentrifuge, Eppendorf model 5415C, Baxter T 
Chemicals 
Dubecco's Modified Eagle's medium (DMEM), 320- 
1965AJ, GIBCO s 
F10 medium, 320-1550AJ s 
Fetal bovine serum (FBS), 200-6000AJ a 
Horse serum, 200-6050AJ s 
Lipofectin, 8292SA s 
8-(4-Chlorophenylthio)-cAMP (CPT--cAMP), C3912, Sigma 9 
Gelatin, porcine, 300 bioom, G25009 
n-Butyryl Coenzyme A (butyryl-CoA), B15089 
N-,N-Bis(2-hydroxyethyl)-2-amino-ethanesulfonic acid (BES), 
391334, Calbiochem 
[3H]chloramphenicol (all-Cm), NET-928, NEN H 
Xylenes, 9490-01, Aldrich lz 
Tetramethyl pentadecane (TMPD), T2,280-2 lz 
Dithiothreatol (DTT), D06379 
Glycylglycine, G22659 
ATP, disodium salt, A64199 
MgSO4 (anhydrous), M75069 
Luciferin, L68829 
KCI, P45049 




NaH2PO 4, S07519 
Ehylenediaminetetraacetic acid (EDTA), disodium salt, 
ED2SS 9 
Scintillation fluid, Betamax, 880020, ICN 13 
C. Cell lines 
F9 teratocarcinoma 
CA-77 medullary thyroid carcinoma 
D. Transfection plasmids-all plasmids were isolated by CsCI 
gradient (twice) and purified by a prëviously described 
protocol (3) 
Bluescript, 212207, Stratagene 14 
RSV-luciferase, provided by Dr. M. Wilkinson, Oregon 
Health Sciences Univ. (5) 
RSV-PKA, provided by Dr. R. Maurer, Univ. of Iowa (22) 
RSV-WTCREB and RSV-KCREB, constructed by cloning 
the cDNAs for wild-type CREB (WTCREB) and the 
mutated CREB (KCREB) into the plasmid RC/RSV, 
lnvitrogen Is (29) 
SS-CAT, contains sequences of the rat somatostatin gene 
from -71  to +53 placed 5' to the gene for chloram- 
phenicol acetyhransferase (24) 
E. Supplies 
Tissue culture plates, 25020 s 
Scintillation vials, R2554-5 r 
Pipettes, sterile, 2 ml, P4676-2; 5 ml, P4676-5:10 tal, 
P4676-10 r 
Micropipette tips, sterile, 1-200 /.tl, 53508-810: 200- 
1000 gl, 1040-800, VWR 16 
Eppendorf tubes, 1.5 ml, sterile, T5050G, Marsh Bio- 
medica117 
Tissue cuhure plate scrapers, T4206-113 
Luminometer vials, 55.484, Sarstedt is 
PROCEDURE 
Preparation of solutions 
1. Phosphate buffered saline (PBS): Dissolve 0.2 g KCI. 
0.2 g KH2PO4, 8.2 g NaCl, 1.1 g NaB2PO, into 900 
ml water, pH to 7.3 with HCI, bring to 1000 rel. 
autoclave. 
2. F9 media: 450 ml DMEM, 50 ml FBS 
3. CA-77 media: 230 ml DMEM, 230 ml F10, 25 ml 
horse serum, 12.5 ml FBS 
4. 2 × BES: 50 mM BES, 280 mM NaC1, 1.5 mM 
NazHPO 4, pH to 6.95 with NaOH. 
5. CaCI z buffer, 0.25 M: dissolve 14.7 g into 90 ml 
water, bring volume to 100 ml, autoclave. 
6. Extraetion buffer 
Dissolve 8.71 g K2PO 4 in 400 ml water, pH to 7.8 
with HCI, bring to 500 ml. Add DTT to 1 mM (77.2 
mg/500 ml) just before use. 
7. CPT-cAMP, 200 mM: dissolve 493.8 mg/5 ml 
water, sterile filter. 
8. Tris-EDTA (TE) buffer: dissolve 1.21 g tris base, 
0.37 g EDTA into 900 ml water, pH to 8.0 with HCI. 
bring volume to 1000 ml, autoelave. 
9. Butyryl-CoA, 2.5 mM: dissolve 2.1 mg/ml water. 
10. Tris buffer, 1 M, pH 7.4: dissolve 121 g tris base 
into 900 ml water, pH to 7.4 with HCI, bring volume 
to 1000 ml, autoclave. 
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11. ATP, 20 mM, pH 7.5: dissolve 12.1 mg/ml water, 
pH to 7.5 by adding 39 #1 1 N NaOH/ml solution. 
12. Luciferase buffer: dissolve 2.18 g glycylglycine, 1.2 
g MgSO4 into 450 ml water, pH to 7.8, bring volume 
to 500 ml. 
13. Luciferase reaction mix: for each reaction, mix 
262.5 gl luciferase buffer, 87.5 #1 ATP. 
B. Gelatin-coated tissue cuhure plates: dissolve 0.7 g gela- 
tin/100 ml water, sterile filter. Add 2 to 3 ml/100 mm 
tissue culture plate, sit at room temperature, 15 min. 
Remove liquid by aspiration and use immediately. Coated 
plates cannot be stored for future use. 
C. Transfection 
1. F9 cells by BES buffer: cells were routinely grown on 
gelatin-coated tissue culture plates at 37 ° C in 5% 
CO2; 3.5 × l0  s cells were plated on lO-cm dishes 
18 h before transfection. DNA was mixed in the fol- 
lowing amounts: 5 #g SS-CAT, 2 gg RSV-luciferase, 
and varying amounts of RSV-PKA, RSV-WTCREB, 
and RSV-KCREB as indicated. Total DNA in each 
transfection was 37 #g, the balance being made up 
with Bluescript. To these were added 0.5 ml of CaC12 
buffer, followed by 0.5 ml BES buffer, and incubated 
at room temperature for 15 min. The mixtures were 
then added to each tissue culture plate and the plate 
incubated overnight at 37 ° C in 3% COz. The media 
were removed, the cells washed once with PBS, fresh 
media added, and the cells placed at 37 ° C in 5% 
CO2. The cells were collected 24 h later. 
2. Ca-77 by lipofectin: cells were routinely grown on 
tissue cuhure plates at 37 ° C in 5% CO z. Cells were 
plated at 5 X 10s/6-cm dish 18 h before transfec- 
tion. In 1.0 ml serum-free media, the following DNA 
was added: 2.5 gg SS-CAT, 2 gg RSV-luciferase, 
and either RSV-WTCREB or RSV-KCREB as indi- 
cated, followed by addition of 30/.tg lipofectin. The 
total amount of DNA in each transfeetion was 30 gg, 
the balance being made up with Bluescript. After the 
cells were rinsed once with serum-free media, 10 ml 
serum-free media and the lipofectin-DNA mix were 
added to each tissue culture plate. Serum to normal 
levels was added after 24 h, followed by addition 6 h 
later of CPT-eAMP to a final concentration of 0.2 
mM. Cells were harvested 36 h after addition of the 
CPT-cAMP. 
D. Harvesting of cells: Cells were rinsed twice with 5 mi 
ice-cold PBS. One milliliter of ice-cold extraction buffer is 
added to each plate, cells collected with a cell scraper, and 
placed in an Eppendorf tube. The cells were spun at 4000 
rpm, 4 ° C, 5 min in a microcentrifuge. The supernatent 
was aspirated, the cells resuspended in 0.1 ml extraction 
buffer, and lysed by three cycles of freeze-thaw by immer- 
sion into dry ice and a 37 ° C water bath. Pellet debris was 
removed by centrifugation, at 15 000 rpm, 4 ° C, 5 min in 
a microcentrifuge, and the supernatent transferred to a 
new Eppendorf tube. Supernatents could be stored frozen 
at - 2 0  ° C for at least 2 wk. 
E. CAT assay: Preparation of [°H]Cm: determine total 
amount of label required (0.2 mCi/tube which is equal to 




vol xylenes, vortex 30 s, microfuge 1 min. Discard xy- 
lenes (top layer) and repeat extraction. Remove traces of 
xylenes by centrifuging under vacuum in speedvac for 5 
min. Prepare a mix of reagents. Volumes per reaction are: 
[3H]Cm, 5 i, tl 
1 M tris buffer 10/.tl 
2.5 mM butyryl CoA 10 #1 
water 45 #1 (this volume based upon a 
cell extract volume of 30/.tl. 
Total reaction volume is 100 #1.) 
Incubate 30 #1 each cell extract in Eppendorf tubes at 
70 ° C for 15 min. Allow to cool on bench, 5 min. Add 70 
#1 reagent mix to each sample, vortex, incubate at 37 ° C, 
2 h. If longer incubations are required due to low activity, 
place samples in a 37 ° C ineubator to inhibit formation of 
condensation on inside top of tube. Terminate reaction by 
addition of 2 vol (200 #1) TMPD:xylenes, 2:1. Vortex 1 
min, sit 5 min, vortex 1 min, microfuge 5 min, and remove 
150/.tl of organic phase (top layer) and place in scintilla- 
tion vial. Add 4 ml scintillation fluid, vortex, and deter- 
mine radioactivity in scintillation counter. 
Luciferase assay: To each tube, add 350 ~tl luciferase 
reaction mix and 10 gl extract. Dilute luciferin as needed 
(100 #l/reaction) to 0.1 mM by addition of 8/.tl stock 
solution to 2 ml water. Place diluted solution in foil- 
wrapped tube to keep it dark. Place samples in carousel 
and luciferin in the injector. Inject 100 gl luciferin per 
reaetion, count for 10 s. 
Data analysis: Because the transfection efficiency can vary 
between tissue culture plates, CAT activity is normalized 
to luciferase activity for each sample. 
DISCUSSION 
We have used these techniques to examine the ability of 
a mutated CREB, KCREB, to act as a dominant repressor 
of CREB in vivo. We had previously determined that in gel 
shift assays, KCREB would block the ability of CREB to 
bind to the somatostatin CRE (29). By transfecting ex- 
pression vectors for CREB, KCREB, and a reporter con- 
struct which would respond to CREB, the ability of 
KCREB to act as an in vivo dominant repressor of CREB 
could be tested. 
The F9 cell hne used for these experiments has little 
CRE response by itself and therefore produces little back- 
ground activity. Because F9 ceUs also have a minimal 
cAMP response eren when CREB is transfected into the 
ceUs, an additional expression construct for PKA is re- 
quired to obtain a stimulated CREB response. In Fig. 1, 
F9 ceUs transfected with CREB produce a significant in- 
crease in activity when cotransfected with PKA. Increas- 
ing the amount of CREB produces a further increase in 
stimulated acüvity. However, when CREB is cotransfected 
with an equal amount of the KCREB mutant, the PKA-in- 
duced stimulation is blocked. Thus, the KCREB mutant 
acts as a dominant repressor of CREB function in vivo. 
Having identified a tool that can be used to eliminate 
the activity of CREB in an in vivo situation, we wanted to 
determine whether it will block an endogenous cAMP-re- 
sponse. The CRE from the somatostatin gene was used for 
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these experiments because CREB was originally cloned 
using the somatostatin CRE as a probe (12,15). Further- 
more, CREB can transactivate the somatostatin promoter 
via the CRE in vivo (1,9,11). However, it has been diffi- 
cult to get direct evidence that CREB is the endogenous 
mediator of the cAMP induction of somatostatin. The CA- 
77 cell line expresses CREB and addition of cAMP ana- 
logues to the cuhure medium stimulates transeription of 
the somatostatin gene. By transfecting KCREB into this 
ceU line, the in vivo role of CREB in the induction of 
somatostatin can be assessed. 
Both wild type CREB (WTCREB) and KCREB were 
transfected into CA-77 cells. CAT activity driven by the 
somatostatin promoter was determined both in unstimu- 
lated and eAMP-stimulated eells. The WTCREB pro- 
duced a modest increase on both basal and stimulated 
expression (Fig. 2). The KCREB construct had no effect 
on basal activity. However, stimulated aetivity was inhib- 
ited by 50%. Doubling the amount of transfected KCREB 
had no further effect on CAT activity. 
The mechanism of action of KCREB is to dimerize with 
the wild-type factor and block its ability to bind the CRE. 
If other factors can dimerize with KCREB, these may also 
be inhibited. Thus, ahhough the 50% inhibition of activity 
indicates that the somatostatin promoter is sensitive to 
KCREB, there may be factors in addition to CREB respon- 
sible for the KCREB-sensitive portion of the induction. 
The fact that approximately 50% of the induction was 
insensitive to KCREB suggests that factors in addition to 
CREB, which do not dimerize with CREB, also participate 
in the cAMP-induction of the somatostatin promoter. 
The expression of specific trans-acting factors and cis- 
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WT 2X WT K:WT 1:1 
TRANSFECTED DNA 
FIG. 1. KCREB blocks the protein kinase A-dependent induction of 
transeription by wild-type CREB. F9 cells were co-transfected with SS-CAT 
(5 gg), RSV-Luc (2 /.lg), and the expression vectors RSV-PKA, RSV- 
WTCREB, and RSV-KCREB. Data are normalized to control activity and 
shown as the mean and standard error of five independent experiments. 
WT. WTCREB (10 gg); 2X WT, WTCREB (20 gg); K:WT 1:1, KCREB ( 10 
~g), and WTCREB (10 v,g). 
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• PLUS CPT-cAMP 
CONTROL WTCRES 23( WTCREB KCREB 2X KCREB 
TRANSFECTED DNA 
FIG. 2. KCREB partially inhibits the cAMP-mediated induction of the 
somatostatin promoter in CA-77 cells. CA-77 cells were co-transfected with 
SS-CAT (5 ~.g), RSV-Luc (1.5 #g), and the expression vectors RSV- 
WTCREB and RSV-KCREB (10 or 20 gg, as indicated). Values are normal- 
ized to control aetivity and represent the mean and standard error of three 
independent experiments. 
allows many questions to be addressed that are difficuh to 
approach by in vitro analyses. The ability of factors to 
transactivate particular enhancer sequences, to respond to 
particular second messenger pathways and the identifica- 
tion of functional domains within the factors are questions 
that have all been addressed by transfection into cell lines. 
Determination of the cis-acting nucleotide sequences re- 
quired for a partictdar response is also readily approach- 
able by transfection into cell lines. Through the use of 
appropriate cell lines, transfection experiments dissecting 
neuropeptide gene expression has produced much infor- 
mation on their mechanism of control and should continue 
to do so in the future. 
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